[ad_1]
NEW YORK, March 9, 2022 /PRNewswire-PRWeb/ — Dracen Pharmaceuticals Inc., a clinical stage biotech company developing anti-cancer drugs that target immuno-metabolism, announced today the company will be presenting an update on the preclinical work and ongoing Phase 1/2a, first- in-human study (FIH) of DRP-104, a broad glutamine antagonist, at the upcoming Festival of Biologics World Immunotherapy Congress and World Antibody Congress taking place March 9 – 11, 2022 in San Diego, California.
Dracen Chief Scientific Officer Robert WildPhD, will discuss how “Sirpiglenastat (DRP-104), a broad acting glutamine antagonist, metabolically reprograms glutamine addicted cancer cells and significantly remodels the tumor …
Full story available on Benzinga.com
[ad_2]
Source link
